A Safety and Pharmacokinetics Trial of VO659 in SCA1, SCA3 and HD

Recruiting now · Phase 1/Phase 2

Conditions studied: Spinocerebellar Ataxia Type 1, Spinocerebellar Ataxia Type 3, Huntington Disease

In brief

The goal of this first-in-human clinical trial is to assess the safety and tolerability of four doses of a new study drug called VO659 in people with genetic disorders called spinocerebellar ataxia type 1, type 3 or Huntington's disease. Another aim is to determine the concentrations of the study drug in the cerebral spinal fluid and blood after single and multiple doses. Study drug will be administered by lumbar intrathecal bolus injections.

Key facts

Study ID
NCT05822908
Run by
Vico Therapeutics B. V.
People needed
68
Starts
2023-02-14
Expected to finish
2028-10-15
Last updated by the study team
2025-08-28

Who can join

Age: 25 and older, up to 60. Sex: any. Healthy volunteers: not accepted.

Where it is running

Full record on ClinicalTrials.gov

Trial information comes from ClinicalTrials.gov and is refreshed daily. TrialsForMe does not provide medical care and does not run the studies it lists.